Article info
PDFClinical quality
NICE guidance for anti-tumour necrosis factor therapy in Crohn's disease: what does it mean for the inflammatory bowel disease community?
- Correspondence to Dr T Orchard, St Mary's Hospital, Imperial College Healthcare NHS Trust, Praed Street, London W2 1NY, UK; t.orchard{at}imperial.ac.uk
Citation
NICE guidance for anti-tumour necrosis factor therapy in Crohn's disease: what does it mean for the inflammatory bowel disease community?
Publication history
- Accepted July 9, 2010
- First published August 5, 2010.
Online issue publication
April 19, 2016
Article Versions
- Previous version (19 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions